Resmetirom side effects

Resmetirom indicated for NASH patients with liver scarring FDA APPROVED resmetirom (Rezdiffra) over a computer rendering of a transparent

resmetirom was superior to placebo in improving fibrosis. 2. Diarrhea and nausea were the most common adverse events associated with resmetirom

resmetirom in real-world settings Later, the pair discuss the importance of monitoring for both efficacy and side effects, including

pazopanib will increase the level or effect of resmetirom by Other (see comment). Avoid or Use Alternate Drug. Avoid coadministration of resmetirom (an OATP1B1/3 substrate) with OATP1B1/3 inhibitors. rifampin. rifampin will increase the level or effect of resmetirom by Other (see comment). Avoid or Use Alternate Drug.

Find patient medical information for Rezdiffra (resmetirom) on WebMD including its uses, side effects and safety, interactions, pictures, warnings, and user ratings

side of the ribs), extreme tiredness, unexplained weight loss and weakness A phase 3 study to evaluate the effect of resmetirom on clinical outcomes in.

We also conducted a scenario analysis assuming no LDL-C benefit for resmetirom and a scenario in which the treatment effects for resmetirom were based on the phase 2 trial results. Under these scenarios, and at its placeholder price, resmetirom remained less costly and more effective than standard care.

Resmetirom (MGL In clinical trials, resmetirom has shown significant reductions in liver fat content in patients with NASH without major side effects.

Further studies of resmetirom will allow assessment of safety and effectiveness of resmetirom in a larger number of patients with NASH with the possibility of documenting associations between histological effects and changes in non-invasive markers and imaging. Funding: Madrigal Pharmaceuticals.